# US 2009/0276019 A1 · Electromagnetic field therapy delays cellular senescence and death by enhancement of the heat shock response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0276019 A1
- Document ID: US20090276019A1
- Status: Published application
- Kind: A1
- Application number: 12/407,616
- Filed: 2009-03-19
- Published: 2009-11-05
- Earliest claimed: 2008-03-19
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Felipe Pablo Perez; Donald A. Jurivich; Jorge Javier Morisaki; Ximing Zhou
- Web page: https://patentgrep.com/patent/US20090276019A1

## CPC

- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- A61N 1/403: {for thermotherapy, e.g. hyperthermia}
- A61N 5/02: using microwaves
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Disclosed herein is a method comprising repetitive electromagnetic field shock to at least one living cell, wherein the repetitive electromagnetic field shock improves HSF1 and/or HSR function, and producing delaying and reversal of aging and age related diseases. Also disclosed herein is an apparatus adapted to deliver repetitive electromagnetic field shock to at least one living cell, wherein the repetitive electromagnetic field shock improves HSF1 and HSR function.

## Claims

### Claim 1

A method comprising:
applying repetitive electromagnetic field shock to at least one living cell, wherein the repetitive electromagnetic field shock is configured to improve either HSF1 or HSR function, or HSF1 and HSR function, without initiating a classical heat shock response.

### Claim 2 (depends on 1)

The method of claim 1, wherein the application of the repetitive electromagnetic field shock is configured to disrupt the molecular brake of HSF1-DNA binding without resulting in a decline of Hsp90.

### Claim 3 (depends on 1)

The method of claim 1, wherein the applying repetitive electromagnetic field shock is at about 50 MHz/0.5 W continuous radiation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the applying repetitive electromagnetic shock is between about 5 minutes to about 30 minutes in duration and is repeated for a period selected from the group consisting of: once a day, about once every two days, about once every three days, about once a week, and about twice a week.

### Claim 6 (depends on 1)

The method of claim 1, wherein the applying repetitive electromagnetic field shock delays or reverses the aging process or at least one age related disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the repetitive electromagnetic field shock is applied to the at least one cell until the cell reaches cellular senescence.

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one cell is a T cell.

### Claim 9 (depends on 1)

The method of claim 1, wherein the at least one living cell is a plurality of living cells, and the method further comprises applying repetitive electromagnetic field shock to a plurality of in vivo living cells.

### Claim 10 (depends on 9)

The method of claim 9, wherein the in vivo living cells are brain cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the repetitive electromagnetic field shock is delivered to at least a localized region of the body of a patient.

### Claim 12 (depends on 1)

The method of claim 1, wherein the repetitive electromagnetic field shock is provided by a transversal electromagnetic chamber.

### Claim 13 (depends on 1)

The method of claim 1, wherein the at least one living cell is a plurality of living cells and the applying repetitive electromagnetic field shock extends the replicative lifespan of the at least one living cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein the applying repetitive electromagnetic field shock extends the terminal lifespan of at least one living cell of the plurality of living cells.

### Claim 15 (depends on 1)

The method of claim 1, wherein the at least one living cell is a plurality of living fibroblast cells and the applying repetitive electromagnetic field shock delays the average age-related enlargement and diversification of at least one fibroblast cell.

### Claim 16 (depends on 1)

The method of claim 1, wherein the at least one living cell is a plurality of living fibroblast cells and the applying repetitive electromagnetic field shock reverts at least one fibroblast cell to a more youthful phenotype.

### Claim 17 (depends on 6)

The method of claim 6, wherein the at least one living cell is a plurality of T-cells and at least a portion of the applying repetitive electromagnetic field shock is applied to the T-cells during IL-2 stimulation.

### Claim 18 (depends on 6)

The method of claim 6, wherein at least a portion of the application of the repetitive electromagnetic field shock is applied concurrently with a treatment that augments the DAF-16 (FOXO) pathway.

### Claim 19

A product comprising:
an apparatus having a power source operatively connected to an electromagnetic fields source and at least one directional coupler, wherein the apparatus is configurable to transmit repetitive electromagnetic field shock at about 50 MHz/0.5 W continuous radiation; and
instructions for operating said apparatus, that if executed, indicate an orientation of at least a portion of a patient's body in relation to the at least one directional coupler during the transmission of the continuous radiation to improve either HSF1 or HSR function, or HSF1 and HSR function, of target cells within said portion of the patient's body, without initiating a classical heat shock response.

### Claim 20 (depends on 19)

The product of claim 19, wherein the instructions provide at least one treatment protocol, wherein the at least one protocol provides an indication for transmitting the continuous radiation for a first time duration and a second time duration, wherein the first and the second time durations are at least about 1 day apart.

### Claim 21 (depends on 19)

The product of claim 19, wherein the instructions provide an indication that the transmission of the continuous radiation from the apparatus will disrupt the molecular brake of HSF1-DNA binding without resulting in a decline of Hsp90.

### Claim 22 (depends on 19)

The product of claim 19, wherein the instructions provide an indication that the transmission of the continuous radiation from the apparatus will extends the replicative lifespan of the at least one living cell within the portion of the patient's body.

### Claim 23 (depends on 19)

The product of claim 19, wherein the instructions provide an indication that the transmission of the continuous radiation from the apparatus will delay the average age-related enlargement and diversification of at least one living cell or reverts at least one living cell to a more youthful phenotype within the portion of the patient's body.
